Drugs / TROP2 CAR/IL-15 TGFBR2 KO NK cells
Follow
re-read 3 minutes ago
TROP2 CAR/IL-15 TGFBR2 KO NK cells
Cell therapy targets TGFBR2 via inhibition
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07631013 | Dec 2026 → Jun 2028 expected | squamous cell carcinoma | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TROP2 CAR/IL-15 TGFBR2 KO NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07631013 ↗ |
| Action | Inhibit | “TGFBR2 KO” NCT07631013 ↗ |
| Modality | Cell therapy | “infused allogeneic donor CAR-transduced CB-derived NK cells” NCT07631013 ↗ |
| Route | Other | “Intralesional TROP2 CAR/ IL15 TGFBR2 KO Engineered Cord Blood-Derived NK Cells” NCT07631013 ↗ |
| Target | TGFBR2 | “TGFBR2 KO” NCT07631013 ↗ |